🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522888-15-00
Completed Phase I

Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer

2025-522888-15-00 · tracked via the Priya Life Science EU tracker
Sponsor
Amgen Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
05/05/2026
Enrollment target
53
Sites
Spain, Germany, Poland, Belgium, France

Condition studied

Small Cell Lung Cancer

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522888-15-00 on CTIS ↗ ← All trials in the EU